Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Site Link Skip to Footer

Research Institute of Radiological & Medical Sciences

  • Greetings
  • History
  • Organization Structure
  • Research Facility and Equipment
  • Division of Radiation Cancer Science
    • Division of Radiation Cancer Science
    • Molecular Imaging Research Center
    • Division of Radiation Effect
    • Research Planning Office
    • Research Center for Radiotherapy
  • Research Project
    • Connection between Government Plan and Medium- to Long-term Improvement Plan
    • Research Center Main Project
    • Main Project Research Field and Portfolio for each target
    • Future Consignment Research Promotion Plan
    • Process Procedure for the National R&D Project

Molecular Imaging Research Center

Home Research Institute of Radiological & Medical Sciences Research Department Introduction Molecular Imaging Research Center

Purpose of the research

Developing radiopharmaceutical lead compounds for the disease targeting and developing in vivo molecular imaging for diagnostic technology and targeted radiotherapeutics using disease specific aninmal models Moreover, we contribute to the development of radiological medical technology using radioisotope (RI) and improvement of diagnosis and treatment rate of intractable diseases where conventional therapy are not appropriate, by establishing radiological medical diagnosis and therapy technology applicable to clinical use

Research field and accomplishments

Development field of lead components for radiopharmaceutical
Development of carbocyclic nucleoside derivatives
Development of carbocyclic nucleoside derivatives
  • Developed a stable compound that is not affected by the hydrolase in the in vivo evaluation by substituting the oxygen atom of sugar with carbon
  • The compounds in the form of carbocyclic nucleoside derivatives for the first time in the radiophamaceutical field ; developing various in vivo, stable radiophamaceuticals using this acquired intermediated compounds
Development of fluorescence tracer with enhanced binding affinity that monitors Beta Amyloid
Development of fluorescence tracer with enhanced binding affinity that monitors Beta Amyloid
  • Developed a fluorescence tracer that combines with the flaque more selectively as the picture on the left in the brain structure of a mouse with Alzheimer’s disease ; it is a fluorescence tracer with increased binding affinity of the compound against the cell and beta amyloid tissue by 6 times, monitoring the beta amyloid flaque that plays an important role in Alzheimer’s disease diagnosis
  • It is expected to be utilized in the research on Alzheimer’s disease using fluorescence imaging
Research field of in vivo molecular imaging diagnostic technology using disease models
Development of transgenic mouse that can be traced for the liver cancer onset process by molecular imaging
Development of carbocyclic nucleoside derivatives
  • Developed a transgenic mouse express reporter protein under the control of alpha-fetoprotein enhancer/promoter ; by using this model, the study of molecular biological relation to hepatocarcinogenesis and screening of potential chemical carcinogen or anticancer drug candidate to liver cancer is possible with molecular imaging method
  • Research on the molecular biological mechanism related to hepatocarcinogenesis by using the molecular imaging method
  • Molecular imaging technology enable to screening chemical carcinogen or therapeutics to liver cancer
Development of fusion imaging of Optics/Nuclear medicine/MR, treatment imaging diagnosis technology in a brain tumor model
Development of fusion imaging of Optics/Nuclear medicine/MR, treatment imaging diagnosis technology 
in a brain tumor model
  • Verified the organism eradiation signal 3 days after the in-brain transplant of U87MG-TL ; the strength of the organism eradiation signal according to cancer growth increased
  • Fusion image of PET/MR of small animal PET image and MR image in an animal model of stereotaxic brain tumor ; By comparing the size of the tumor measured in MR and standardized uptake value in small animal PET image, a close correlation from the each measured tumor images shows highly dependence on size correlations of the tumor measured with two images
  • Nuclear medicine being used in clinics ; development of multiple imaging technologies that combine MR imaging and optical imaging technology with high utilization in the preclinical phase, facilitated performance as clinical research
Radio isotope (RI) targeted therapy technology development field
Development of tumor-targeted small animal PET Imaging technology using protein
Development of tumor-targeted small animal PET Imaging technology using protein
  • Acquired radioactive isotope I-124 or gamma camera image of 3E8 Fab indicated as Ga-68 (below) from the LS174T tumor model and small animal PET image (above)
  • Radioimmuno therapy technology as a substitute therapy is in the spotlight as therapy against tumors that do not respond to the existing treatment by increasing the survival rate and improving the quality of life during the survival period
Multi-modality fusion imaging technology development field
Development of multi-modality fusion imaging technology to disease models
Development of multi-modality fusion imaging technology to disease models
  • Development of preclinical PET and CT image fusion technology and analysis optimization method for functional improvement of localized metabolic tumor evaluation
  • Using small animal disease model, preclinical imaging evaluation method is expected to be improved quantitative and quantificational evaluation method for in vivo functional metabolism
Discovering a malignant tumor prediction model using molecular imaging fusion technology
Discovering a malignant tumor prediction model using molecular imaging fusion technology
  • By discovering the post-therapy prediction model against malignant osteosarcoma therapy by combining MRI and PET using radio isotope, suggested improvement direction for osteosarcoma-therapeutic efficiency
  • The effect of treatment improvements expected through the suitable assessment of the response of intractable cancer by suggesting an evaluation model through fusion imaging system for new therapeutic response evaluation
Development of next-generation, multi-functional SPECT/MR bimodal contrast agent
Discovering a malignant tumor prediction model using molecular imaging fusion technology
  • Developed SPECT/MR bimodal contrast agents with low-dose molecules for the first time in Korea, verified with in vitro experiment and in vivo imaging
  • The compound of the bimodal contrast agents itself can be used as nuclear medicine and MRI medicine, providing the multi-function imaging functionality ; its utilization in next-generation, new-function, multi-functional imaging drug development is expected
Clinical test field for radioimmunity treatment researchers
Development of I-131 label rituximab (anticancer medication) radioimmuno therapy and researcher clinical test protocol
Discovering a malignant tumor prediction model using molecular imaging fusion technology
  • One-time treatment, repeat treatment, and advertisement treatment radioimmuno therapy were administered with I-131 label rituximab (anticancer medication) for non-responsive lymphoma patient and development of researcher clinical test protocol
  • Treatment effect followed by administration of radioimmuno therapy was evaluated with FDG-PET imaging The result of administering radioimmuno therapy repeatedly to non-responsive lymphoma patients showed improved treatment responding rate

Future research and development plan

  • Development of diagnosis and therapy for intractable disease using convergence Radioisotope
  • Development of new-concept multi-application fusion nuclear imaging technology based on next-generation imaging